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MeCP2MECP2mutations cause the X-linked neurodevelopmental disorder Rett Syndrome (RTT) by consistently altering
the protein encoded by the MECP2e1 alternative transcript. While mutations that simultaneously affect both
MECP2e1 and MECP2e2 isoforms have been widely studied, the consequence ofMECP2e1 deﬁciency on human
neurons remains unknown. Here we report the ﬁrst isoform-speciﬁc patient induced pluripotent stem cell
(iPSC) model of RTT. RTTe1 patient iPS cell-derived neurons retain an inactive X-chromosome and express
only the mutant allele. Single-cell mRNA analysis demonstrated they have a molecular signature of cortical
neurons. Mutant neurons exhibited a decrease in soma size, reduced dendritic complexity and decreased cell
capacitance, consistent with impaired neuronal maturation. The soma size phenotype was rescued cell-
autonomously by MECP2e1 transduction in a level-dependent manner but not by MECP2e2 gene transfer.
Importantly, MECP2e1 mutant neurons showed a dysfunction in action potential generation, voltage-gated
Na+ currents, and miniature excitatory synaptic current frequency and amplitude. We conclude thatMECP2e1
mutation affects soma size, information encoding properties and synaptic connectivity in human neurons that
are defective in RTT.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Rett Syndrome (RTT) is a neurodevelopmental disorder
[OMIM312750] characterized by repetitive hand motions and loss of
acquired language (Chahrour and Zoghbi, 2007). Heterozygous loss-
of-function mutation in the X-linked gene encoding Methyl-CpG Bind-
ing Protein 2 (MECP2) is the prime cause of RTT in girls (Amir et al.,
1999). This gene is alternatively spliced into MECP2e1 and MECP2e2
isoforms that encode distinct proteins differing at the N-termini due
to exclusion or inclusion of exon 2 respectively (Kriaucionis and Bird,
2004; Mnatzakanian et al., 2004). Mutations that affect both isoforms
have beenwidely studied, and the role ofMECP2 in bindingmethylated
and hydroxy-methylated cytosine genome-wide (Mellen et al., 2012;
Skene et al., 2010) to recruit chromatin-remodelling proteins thatStemCell Biology, TheHospital
earning, Rm 16-9715, 686 Bay
252.
ect.com).
. This is an open access article undermodulate global transcription is now well established (Chahrour et al.,
2008; Lyst et al., 2013). TALEN-mediated mutagenesis of the MECP2
locus demonstrated that MECP2 ablation results in global decreases in
gene transcription and translation in a human ES cell-based model of
RTT (Li et al., 2013). These defects were manifest in abnormal neuronal
morphology and function, including impaired mitochondrial function.
The majority of RTT patient mutations affect both isoforms but
identiﬁcation of individuals with a MECP2e1-speciﬁc mutation that
does not alterMECP2e2 indicates that MECP2e1 isoform dysfunction is
sufﬁcient to cause RTT (Mnatzakanian et al., 2004). A recent report of
a Mecp2e1-speciﬁc mouse model of RTT further suggests that this
MECP2 isoform is responsible for RTT-related behavioural abnormalities
(Yasui et al., 2014), but the effect ofMECP2e1 deﬁciency on humanneu-
rons has not been evaluated. In contrast, noMECP2e2-speciﬁcmutations
have been described in RTT patients, and Mecp2e2-mutant mice lack
neurological phenotypes and instead exhibit placental defects (Itoh
et al., 2012). However, expression of either Mecp2e1 or Mecp2e2 can
improve a subset of RTT-related behavioural phenotypes in Mecp2-
null mice (Kerr et al., 2012). These ﬁndings suggest that endogenous
MECP2e1 is essential for normal brain function, but Mecp2e2 can
ameliorate certain disease features in mouse models of RTT.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
38 U. Djuric et al. / Neurobiology of Disease 76 (2015) 37–45We, and others, reported the generation of human and mouse
induced pluripotent stem cells (hiPSCs and miPSCs, respectively) from
RTT patients and mouse models that carry pathogenic mutations in
both MECP2 isoforms (Ananiev et al., 2011; Cheung et al., 2011; Kim
et al., 2011). RTT iPSC-derived neurons exhibit maturation and electro-
physiological defects reminiscent of those seen in RTT patients and
mouse models (Farra et al., 2012) and are amenable to rescue by intro-
duction of exogenous MECP2 or drugs such as IGF1 (Li et al., 2013;
Marchetto et al., 2010). Generally, female RTT-hiPSCs retain an inactive
X-chromosome (Xi) (Pomp et al., 2011; Tchieu et al., 2010) and express
either the wild-type (WT) or mutantMECP2 allele and this expression
pattern is conserved upon differentiation into neurons (Cheung et al.,
2012). Here, we generated hiPSC-derived neurons that express mutant
MECP2e1. Using this system, we ﬁnd thatMECP2e1mutation affects the
soma size and electrophysiological properties of human neurons.
Materials and methods
Cell culture
RTTe1-ﬁbroblasts were obtained from Dr. Patrick Macleod at the
Victoria General Hospital, Victoria, BC, Canada, and cultured under the
approval of the SickKids Research Ethics Board and Canadian Institutes
of Health Research Stem Cell Oversight Committee. Fibroblasts were
maintained in ﬁbroblast medium: Dulbecco's Modiﬁed Eagle Medium
(DMEM) containing 10% Fetal Bovine Serum, and 100× penicillin and
streptomycin (all from Invitrogen). RTTe1-hiPSCs were generated
from ﬁbroblasts and maintained in hiPSC medium as previously de-
scribed (Hotta et al., 2009).
Androgen receptor assay
To identify the methylated Xi, 200 ng of DNA was digested overnight
at 37 °Cwithmethylation-sensitive enzymesHpaII andHhaI (Invitrogen).
To discriminate between the two parental X-chromosomes, 20 ng of
digested and undigested DNA was ampliﬁed with primers spanning the
heterozygous polymorphic trinucleotide repeat in the ﬁrst exon of the
AR gene for 32 cycles. The 5′ end of the forward primer was labelled
with FAM ﬂuorescein (Invitrogen). PCR products were separated on
an ABI3100 Genetic Analyzer with 500 LIZ size standard and analysed
by Peak Scanner software (all from Applied Biosystems). XCI ratio
(Table S1) was calculated as previously described (Cheung et al., 2011).
In vitro and in vivo differentiation
For in vitro differentiation, hiPSCs were detached and grown in sus-
pension in hiPSC medium (Hotta et al., 2009) without FGF2 for eight
days to form embryoid bodies. Embryoid bodies were adhered and
allowed to further differentiate for eight days. Differentiated derivatives
were analysed via immunocytochemistry with appropriate antibodies
(Table S4). For in vivo differentiation, one 10 cm dish of hiPSCs was de-
tached and suspended in a mixture of KNOCKOUT DMEM (Invitrogen),
Matrigel (BD Biosciences), Collagen (STEMCELL Technologies) (ratio
2:1:2), and 10 μMROCK Inhibitor (Sigma) and injected intramuscularly
into immunodeﬁcient mice. Fixed tumours were embedded in parafﬁn,
sectioned, and stained with haematoxylin and eosin for pathological
analysis. All procedures using animals were approved by the SickKids
Animal Care Committee under the auspices of The Canadian Council
on Animal Care, and conducted with the approval of the Canadian
Institutes of Health Research Stem Cell Oversight Committee.
Immunocytochemistry
Cells were ﬁxed with 4% formaldehyde (EMD Biosciences) for
10 min at room temperature (RT), permeabilized with 0.1% Nonidet
P-40 (Sigma). Blocking was performed for 3 h at RT, primary antibodiesdiluted in block solution and incubated overnight at 4 °C (See Table S4
for antibodies used). Imageswere captured using a Leica DMI4000Bmi-
croscope equipped with Leica DFC340FX camera and Leica Application
Suite software for hiPSCs or Zeiss Axiovert 200M microscope equipped
with a Hamamatsu C9100-13 EMCCD camera and Improvision
Volocity software for neurons. Soma size of neurons was scored using
Improvision Volocity software on 40× images blinded to the observer.
Neuronal differentiation
The Brennand protocol with slight modiﬁcations (Brennand et al.,
2011; Chambers et al., 2009) was used for neuronal differentiation of
the RTTe1#27 line (Table S2). The Kim protocol with slight modiﬁca-
tions (Kim et al., 2012) or the Brennand protocol with the addition of
DAPT in the medium was used for the remaining lines (Table S2).
Analysis was compared to WT-neurons generated with the same
protocol. Soma-size measurements were performed as described
(Cheung et al., 2011). See supplemental material for more details.
Generation and transduction of lentivirus
MECP2 isoform-speciﬁc lentiviruses were previously reported
(Rastegar et al., 2009). The generation and transduction of lentivirus
were performed as previously described (Hotta et al., 2009). In brief,
plasmids containing cDNA of interest were transfected into 293T cells
using Lipofectamine 2000 (Invitrogen). The supernatant containing
the virus was collected two days post-transfection and concentrated
by ultracentrifugation. 293T cells were maintained in Dulbecco's Modi-
ﬁed Eagle Medium (DMEM) containing 10% Fetal Bovine Serum, and
100× penicillin and streptomycin, MEM NEAA (all from Invitrogen).
Titration of lentivirus was performed as previously described (Hotta
et al., 2009). In brief, 293T cells were transduced with EF1α-EGFP
lentivirus. Titer (infectious units, IU) of lentivirus was calculated
with the following formula: Viral titer (IU ml−1) = [Infected cell
number] × [EGFP+%/100]/[Amount of virus used (ml)]. Transduction
of NPCs was performed in the presence of 0.6 μg ml−1 Hexadimethrine
bromide (Sigma) for six hours with a multiplicity of infection (MOI) of
one calculated for 293T cells.
RNA isolation, RT-PCR and cDNA sequencing
RNA was isolated using Trizol extraction method (Invitrogen) and
SSII RT (Invitrogen) was used for the reverse transcription following
manufacturer's instructions. Primers for the Real-Time PCR assays
were designed using Primer3 online primer design software and qPCR
was carried out using SYBR green (Applied Biosystems) on an ABI
7900HT PCR System (Applied Biosystems). To sequence RTTe1-hiPSC
cDNA, RT-PCR was performed using V1 primers (Table S3). The
MECP2e1 amplicon (382 bp or 371 bp for WT or mutant allele, respec-
tively) was gel puriﬁed from the MECP2e2 amplicon (506 bp) using
QIAquick PCR Puriﬁcation Kit following manufacturer's instructions
and sequenced using the V1-f for ampliﬁcation.
Bisulﬁte sequencing
Bisulﬁte conversionwas performed as previously described (Fussner
et al., 2011). Brieﬂy 1 μg of DNA was subjected to conversion using the
DNA Methylation Gold Kit (Zymo Research). 50 ng of converted DNA
was subjected to PCR with appropriate primers (Table S3).
Single-cell ﬂuidigm array
Neurons were subjected to single cell sorting and Fluidigm analysis
as described (Pasca et al., 2011). Single cell sorting was performed by
The Flow Cytometry Facility at The Hospital for Sick Children (Toronto,
Ontario, Canada) using MoFlo BRU cell sorter (Beckman Coulter). Cells
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CellsDirect ampliﬁcation master mix (Invitrogen) into 96-well plates.
RT reaction and 15 rounds of cDNA ampliﬁcation were performed
using primers to genes of interest (Table S3). Fluidigm Biomark qPCR
assays were performed by Janet Rossant lab at The Hospital for Sick
Children (Toronto, Ontario, Canada). Data analyses and generation of
ﬁgures were performed using R-Statistical analysis software (http://
cran.r-project.org). For neuronal identity quantiﬁcations, cells were
deemed neurons if expressing NCAM or MAP2 with: FOXP1 and ETV1
double positive (lower layer); FOXP1-/ETV1-/CUX1+/SATB2+/CTIP2+/Fig. 1. Generation and pluripotency characterization of RTTe1-hiPSCs. (A) Androgen receptor (
lines. Bar graph depicts XCI ratio of two X chromosomes (X1 and X2). Fib., ﬁbroblasts. (B) qRT
pluripotency genes in RTTe1-hiPSC lines. Data are expressed as mean ± SEM. (D) Bisulﬁte seq
closed CpG sites indicate unmethylated and methylated CpG sites, respectively. (E) RTTe1-hiP
RTTe1-hiPSC#39 teratomas). Scale bars, 50 μm (immunocytochemistry) and 100 μm (histologREELIN+ (upper layer); CAMK2+, VGLUT1+, VGLUT2+ or VGLUT3+
(glutamatergic); GAD67+ or VGAT+ (GABAergic) (Pasca et al., 2011).
Western blot analysis
Nuclear proteins were collected using nuclear extraction protocol,
samples were aliquoted and snap frozen in liquid nitrogen for storage
until western blots were performed. 5 μg of total protein was loaded
for western blots, transferred to nitrocellulose membranes overnight
at 4 °C Membranes were blocked in 5% Milk PBS-T and incubatedAR) methylation screen of RTTe1-hiPSCs demonstrates skewed XCI ratios in all examined
-PCR analyses of pMXs reprogramming retroviral transgenes. (C) qRT-PCR of endogenous
uencing of retroviral pMXs-LTR reprogramming vectors in RTTe1-hiPSC lines. Open and
SCs differentiate into the three germ layers in vitro and in vivo (representative images of
y).
40 U. Djuric et al. / Neurobiology of Disease 76 (2015) 37–45overnight in primary antibodies (see Table S4), washed 5 times in PBS-T
and incubated in appropriate HRP-conjugated secondary antibodies
(Invitrogen) for 1 h at room temperature. Densitometry measurements
and normalization (to Histone H3 signal) was performed using ImageJ
software.
Karyotyping
Standard G-banding chromosome analysis with a 400–500 banding
resolution was performed at The Centre of Applied Genomics (TCAG
[The Hospital for Sick Children, Toronto, Canada]).
Electrophysiology
Electrophysiology was performed as described (Farra et al., 2012).
See supplemental information for detailed protocol.
Results
Isolation of mutant RTTe1-hiPSCs through XCI
Fibroblasts acquired from an RTT patient with an 11 base-pair
(bp) deletion in exon 1 of MECP2 (RTTe1) were used to generate
RTTe1-hiPSCs via retroviral transduction of human OCT4, SOX2,
KLF4, and c-MYC. This exon 1 speciﬁc NM_001110792.1:c.47_57del; p.
(Gly16Glufs*22) mutation causes a frameshift resulting in severely
truncated MECP2e1 but intact MECP2e2 (Mnatzakanian et al., 2004).
We used the Androgen Receptor (AR) assay to determine the X-
inactivation status in RTTe1-hiPSCs, revealing that all of the 22 RTTe1-
hiPSC lines exhibited XCI skewing (80:20–~100:0) towards the same
parental X-chromosome (Fig. 1A, Table S1). We selected four RTTe1-
hiPSC lines for detailed pluripotency characterization (Table S2). All
four hiPSC lines silenced and methylated the reprogramming retroviral
transgenes, activated the pluripotency-related genes (Figs. 1B–D)
and had normal karyotypes (Fig. S1). Embryoid body-mediated sponta-
neous in vitro and teratoma-based in vivo differentiation assays
demonstrate that RTTe1-hiPSC lines give rise to cells of all three germ
layers (Fig. 1E). Collectively these data demonstrate that the generated
hiPSC lines are of high quality appropriate for RTT diseasemodelling. To
determine the identity of the active X-chromosome, we performed
MECP2 cDNA sequencing with primers spanning the 11 bp deletion
revealing that the RTTe1-hiPSCs solely expressed the mutant alleleFig. 2. RTTe1-hiPSCs and -neurons retain an Xi and exclusively express the mutantMECP2e1 all
expressing X-chromosome contains the 11 bp RTTe1 deletion (left panel), with representative
mutantMECP2 allele (left panel) and share the same inactive X chromosome revealed by the A(Fig. 2A). To ensure that neither a change in the Xi nor Xi erosion
(Mekhoubad et al., 2012) occurred during differentiation, we
conﬁrmed persistent expression of the mutant MECP2e1-containing
X-chromosome using cDNA sequencing and the AR assay on hiPSC-
derived neurons (Fig. 2B) (see below for neuronal characterization).
Directed differentiation into cortical neurons expressing mutant MECP2e1
To generate neurons in vitro, we found that the Brennand protocol
efﬁciently differentiated the RTTe1#27 line into neuronal progenitor
cells (NPCs) and neurons while the remaining three RTTe1-hiPSC lines
required optimization using previously described protocol variations
(Table S2) (Brennand et al., 2011; Kim et al., 2012). Cumulative results
using neurons derived from all four RTTe1-hiPSC lines are shown for
subsequent experiments, and the RTTe1#27 line was utilized for all ge-
netic rescue studies. We observed a 10-fold increase in MECP2 mRNA
upon transition of RTTe1-NPCs into neurons (Fig. 3A). Since we were
unable to establish RTTe1-hiPSCs expressing the wild-type allele, we
compared RTTe1-neurons to those transduced by a lentiviral vector
expressing MECP2e1-MYC under the control of the Mecp2 promoter
(MeP) or the ubiquitously expressed EF1α promoter (Rastegar et al.,
2009). Vector transduction resulted in speciﬁc increase of MECP2e1
mRNA in differentiated MeP neurons (Fig. 3B). Total MECP2 protein
moderately increased in MeP transduced cells, and was higher in the
EF1α transduced cellswhileMECP2e2 protein levels remained unaffect-
ed (Fig. 3C). The relative levels of exogenous MECP2 are most easily
quantiﬁed by densitometry using theMYC antibodywhich has a cleaner
signal than MECP2, indicating that the EF1α vector expresses roughly
twice as much MECP2e1-MYC protein as MeP in neurons similar to
the qRT-PCR data shown in Fig. 3B. These results demonstrate that
RTTe1 cells continue to express MECP2e2 while the vector transduced
cells express different levels of exogenous MECP2e1 protein.
To investigate neuronal identity of the differentiated RTTe1-hiPSC
lines, we characterized single cell mRNA proﬁles using Fluidigm arrays
(Pasca et al., 2011). More RTTe1-MeP cells were expressing the mature
neuronal markers DCX, NCAM and MAP2 compared to RTTe1 mock
infected cells but, importantly, both RTTe1 mock and RTTe1-MeP cells
were of comparable neuronal types (Fig. 3D). These included cells
with a dorsal forebrain identity indicated by PAX6 expression, a roughly
60:30% distribution of lower and upper cortical layer neurons,
respectively; and an equal (~35:45%) mixture of glutamatergic and
GABAergic neurons (Fig. 3E), based on concurrent expression ofele. (A) cDNA sequencing ofMECP2e1 transcripts in selected RTTe1-hiPSCs reveals that the
chromatogram (right panel). (B) Differentiated RTTe1-neurons maintain expression of the
R assay (right panel).
Fig. 3. RTTe1 neurons maintain normal balance of neuronal identities. (A) Transcription of bothMECP2 isoforms increases over the course of neuronal differentiation. (B) MeP-MECP2e1
and EF1α-MECP2e1 lentiviral constructs are expressed in mature RTTe1#27 neurons. Data are expressed as mean ± SEM. (C)Western blot analysis of transduced RTTe1#27 cells shows
that MeP-MECP2e1 rescue results in amoderate increase of totalMECP2 protein, and detectable levels of theMYC taggedMECP2e1with unchanged levels of MECP2e2 protein. Transduc-
tion with EF1α-MECP2e1 construct leads to overexpression of total MECP2 protein and higher levels of MYC tagged MECP2e1. Densitometry bar graph is shown with normalization to
loading control, histone H3. (D) Bar graphs show comparable percentage of cells expressing majority of neuronal markers as determined by Fluidigm arrays in RTTe1-mock (cumulative
data from all 4 RTTe1 lines) and MeP rescued RTTe1#27 cells. Data are expressed as mean ± SEM; *P b 0.05. (E) Similar percentages of cortical layer and neurotransmitter neurons are
produced from both RTTe1-mock and MeP rescue cells. Data are expressed as mean ± SEM; *P b 0.05.
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rays (see Materials and Methods). To determine the consequences on
neurons that lack both isoforms, we compared neurons derived from
previously generatedMECP2 null iPS cells (Δ3-4#20) to their isogenic
(Δ3-4#37) MECP2 WT-neurons (Cheung et al., 2011). The Fluidigm
array results showed that complete absence of MECP2 also did not
dramatically alter the type of neurons generated (Figs. S2A and S2B).
Collectively, these results indicate that lack of MECP2e1 has minimal
effects on neuronal differentiation fate in vitro and that cortical neurons
relevant to RTT phenotypes were generated.
MECP2e1 is a level-dependent cell-autonomous regulator of soma size
RTT is thought to be a neurodevelopmental disorder with defects in
neuronal maturation and/or maintenance (Kishi and Macklis, 2004;
Nguyen et al., 2012). To determine whether the loss of MECP2e1
alone results in a neuronal phenotype, we measured soma size in
RTTe1-neurons. All 4 RTTe1-hiPSCs lines were differentiated intoMAP2-positive neurons, with negligible MECP2, consistent with con-
tinued low-level expression of MECP2e2 and showed signiﬁcant de-
crease in soma size compared to WT-neurons derived from Δ3-4#37
(Fig. 4A). Cumulative data of RTTe1-neurons derived from all 4 lines
also showed a signiﬁcant decrease in soma size compared to WT-
neurons derived from Δ3-4#37 (Fig. 4B, bars 1 and 2). In addition,
sparse transfection with an EF1α-EGFP reporter was used to label
single neurons and conﬁrmed that dendrite length, tip number and
complexity are reduced in RTTe1-neurons relative to WT-neurons
(Fig. S3). These RTT-associated morphological phenotypes suggest
that MECP2e1 is important for neuronal maturation.
To test whether the easily measured soma size defect is due to
MECP2e1 mutation, RTTe1#27-NPCs were infected with MECP2e1
lentiviral vectors prior to the ﬁnal neuronal differentiation step. Trans-
duced NPCs expressed the ubiquitous EF1α-vector while the MeP
construct was only activated upon neuronal differentiation (Fig. S4A
and S4B). These results demonstrate temporal regulation of the MeP
promoter during maturation of human neurons in vitro. Co-staining
Fig. 4. RTTe1-neurons exhibit a soma size defect that can be rescued byMECP2e1 in a cell-
autonomous manner.(A) Immunocytochemistry for MAP2 and MECP2 in WT Δ3-4#37
and RTTe1#27 neurons. Bar graph represents soma size analysis of neurons derived
from individual RTTe1 hiPS cell lines compared to WT neurons derived by three differen-
tiation protocols utilized in the study. (B) Immunocytochemistry for MAP2 and MYC in
RTTe1#27-neurons with or without MECP2e1-vectors. Bar graph shows cumulative
soma size analysis of all four RTTe1-neurons, and RTTe1#27 neurons with MECP2e1-
vectors compared to WT-neurons. Total number of measured neurons for each analysed
genotype is indicated within the appropriate bar. Data are expressed as mean ± SEM
(*P b 0.001; Student's t-test; n = at least 3 independent differentiations). Scale bars,
44 μm for large image, 10 μm for inset. Arrows, MYC-positive neurons. Arrowheads,
MYC-negative neurons.
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expressed lentiviral transgenes (Fig. 4B). Therefore, soma size was
scored inMYC-positive relative toMYC-negative neurons. No statistical-
ly signiﬁcant differences were observed in the EF1α-transduced
neurons (Fig. 4B, bars 3 and 4). These neurons express twice the level
of MYC tagged MECP2e1 protein (Fig. 3C), which may be incompatible
with rescue of neuronal morphology phenotypes similar to the ﬁnding
that MECP2 duplication causes neurological phenotypes. Only the
MeP-transducedMYC positive neurons showed a statistically signiﬁcant
soma size increase in comparison to the adjacentMYC negative neurons
(bars 5 and 6). Mock infected cells were all MYC-negative with small
soma size (bars 7 and 8). These results reveal that soma size is rescued
byMeP-MECP2e1 in a cell- autonomous manner.To assess whether the soma size phenotype is due to the speciﬁc
absence of MECP2e1, we performed additional transductions of
RTTe1#27-NPCswithMECP2e2 vectors. MECP2e2was poorly expressed
by the MeP promoter in neurons, likely due to its shorter protein half-
life (Yasui et al., 2014). Therefore, higherMeP-MECP2e2multiplicity of
infection (MOI) was used to obtain MAP2 positive neurons with
detectable MYC signals (Fig. 5A). As expected, the control MYC-
positive MeP-MECP2e1 transduced neurons rescued the soma size
equivalent to WT-neurons and the EF1α-MECP2e2 transduced neurons
showed no statistically signiﬁcant differences in soma size (Fig. 5B).
Strikingly, theMeP-MECP2e2 vector was unable to rescue (Fig. 5B). We
observed that the mRNA levels inMeP-MECP2e2 transduced cells were
greater than that in MeP-MECP2e1 (Fig. 5C) but the MYC intensity in
MeP-MECP2e2 transduced neurons was not (Fig. 5B). Because soma
size can only be measured in single cells, the most accurate comparison
of the two rescue vectors was to identify single neurons expressing
similar protein levels by binning intracellular immunoﬂuorescence
intensity levels of the MYC signal. MYC signal intensity covered the
same range (3600–30,000 arbitrary units) in both the MeP-MECP2e1
andMeP-MECP2e2 transduced neurons. We found that low expressing
MeP-MECP2e1 RTTe1 neurons (3600–5000 arbitrary units) have a
soma size rescue that is statistically signiﬁcantly different from the
high MECP2e1 expressing and mock infected cells, conﬁrming that
MECP2e1 rescue is level-dependent (Fig. 5D). On the other hand,
neither high (greater than 8000 arbitrary units) nor the similarly low
MeP-MECP2e2 expressing RTTe1 cells had a soma size rescue. Since
both isoforms contained the same C terminal MYC tag and were
expressed from the same vector, the rescue is not due to tag or vector
effects. We conclude that MECP2e2 is unable to efﬁciently rescue
soma size in our systemwhen comparing single cells expressing similar
levels of the MECP2 isoform transgenes. These data indicate that
MECP2e1 is a cell-autonomous regulator of soma size.
MECP2e1 controls action potentials and excitatory synaptic responses
We next determined whether glutamatergic RTTe1-neurons exhibit
any electrophysiological defects. Whole-cell patch-clamp recordings
were performed on over 220 hiPSC-derived neurons from two WT
(characterization of SK0019_002#7 hiPSCs is in Fig. S5) and four
RTTe1 lines. Electrophysiological studies demonstrated RTTe1-neurons
compared with WT-neurons had higher input resistance (Fig. 6A), and
lower cell capacitance (Fig. 6B) dependent on the membrane area of
the cells (Golowasch et al., 2009; Limon et al., 2005), corresponding to
the decrease in soma size in RTTe1-neurons. There is no signiﬁcant
difference in the resting membrane potentials between WT- and
RTTe1-neurons (Fig. S6A). These hiPSCs-derived cells had functional
neuronal properties and generated tetrodotoxin-sensitive Na+
channel-mediated spontaneous and/or evoked action potentials
(Fig. 6C, Fig. S6C and S6D). However, evoked action potentials in
RTTe1-neurons exhibited smaller amplitude, longer time course
(increased rise time, half-duration, and decay time), and fewer numbers
as a series of current stepswere injected (Fig. 6D, Fig. S6E-I). The defects
in generating action potentials in RTTe1-neurons could be attributed to
a decrease in voltage-gated Na+ currents. Indeed, signiﬁcant decreases
in amplitude and density of voltage-gated Na+ currents were observed
in RTTe1-neurons (Fig. 6E, Fig. S6B). There was no signiﬁcant difference
in voltage-gated K+ currents between WT- and RTTe1-neurons. These
ﬁndings indicate that RTTe1-neurons have deﬁciencies in intrinsic
membrane properties similar to neurons with MECP2 null mutation
(Calfa et al., 2011; Farra et al., 2012; Zhang et al., 2010).
The other evidence demonstrating the functional neuronal proper-
ties of these hiPSC-derived cells is that WT- and RTTe1-neurons
displayed spontaneous synaptic activity (Fig. 7A and Fig. S7). Studies
from us (Farra et al., 2012) and other investigators (Chao et al., 2007;
Dani et al., 2005; Marchetto et al., 2010; Nelson et al., 2006) have
shown that neurons withMECP2 null mutation have synaptic defects.
Fig. 5. Soma-size rescue is MECP2e1 level-dependent. (A) Immunocytochemistry for MAP2 and MECP2 or MAP2 and MYC in RTTe1-neurons with or withoutMECP2e2-vectors and WT-
neurons. Scale bars, 44 μm for large image. Arrows, MYC-positive neurons. Arrowheads, MYC-negative neurons. (B) Soma size analysis of RTTe1-neurons with or without MECP2e1
(control) or MECP2e2 vectors compared to WT-neurons. Number of measured neurons for each analysed genotype is indicated within the appropriate bar. (C) qRT-PCR of totalMECP2
and the lenti-derivedMECP2 transcripts in cells transduced with either MECP2e1 or MECP2e2 vectors. (D) Soma size analysis in cells expressing low or high levels of MECP2, based on
immunostaining intensities of the MYC signal. Data are expressed as mean ± SEM (*P b 0.001; Student's t-test; n= 3 independent differentiations).
43U. Djuric et al. / Neurobiology of Disease 76 (2015) 37–45Thus,we recordedminiature excitatory postsynaptic currents (mEPSCs)
to examine whether RTTe1-neurons have any defects in synaptic func-
tion. Estimates of mEPSCs uncovered that RTTe1-neurons displayed
dysfunctional synaptic activities with signiﬁcant decreases in both
amplitude (Fig. 7B) and frequency (Fig. 7C) of mEPSCs. Collectively,
these ﬁndings demonstrate that MECP2e1 controls physiological prop-
erties of neurons and its loss triggers immature neuronal phenotypes
that are related to reduced soma size and synaptic connectivity.
Discussion and conclusions
We developed RTTe1 patient iPSCs to discover the effect ofMECP2e1
mutation on human neurons. RTTe1-hiPSCs retained an Xi allowing the
generation of mutant MECP2e1 neurons upon differentiation. This
feature of X-inactivation during reprogramming with a preferential
retention of one speciﬁc Xi in human iPS cell lines has been previously
observed by us and others (Cheung et al., 2011; Pomp et al., 2011).
Single cell Fluidigm arrays demonstrated that the majority of neurons
were cortical in nature with an equal mixture of glutamatergic and
GABAergic neurons, and the relative proportion of cell types was
unaffected byMECP2e1 orMECP2 null mutations.
We next investigated the effect of MECP2e1 mutation on neuronal
form. RTTe1-neurons displayed a soma size defect and reduced dendrit-
ic complexity in comparison toWT-neurons. The soma sizewas rescued
with a MECP2e1 transgene. The rescue effect was cell-autonomous as
only RTTe1-neurons that received the vector and not their uninfected
neighbours exhibited a soma size increase. These results are consistent
with the ﬁnding that nuclear size is cell- autonomously regulated by
Mecp2 in mouse ES cell derived neurons (Yazdani et al., 2012). The
heterogeneous expression of the MECP2e1 transgene in our system
allowed us to determine that transduced single cells expressing low
levels of MECP2e1 had a soma size rescue comparable to WT neurons.
Thus MECP2e1 rescue is level-dependent, in agreement with ﬁndingsthat mild overexpression of MECP2 results in neurological phenotypes
(Collins et al., 2004). In contrast MECP2e2 transgenes regulated by the
same promoter in single neurons with similar low MYC staining inten-
sity did not rescue the soma size of RTTe1 neurons. Since Mecp2e2
transgenes can rescue certain behavioural RTT phenotypes in mice
(Kerr et al., 2012), we cannot exclude the possibility that a particular
level of MECP2e2 expression during neurodevelopment may rescue
some function in neurons. Taking the rescue experiments together
with the reproducibility of the soma size defect in neurons derived
from all 4 RTTe1-hiPSC lines, we conclude that MECP2e1 mutation
reduces soma size in human neurons.
Finally, we evaluated the effect of MECP2e1 on neuronal function by
identifying electrophysiological defects in RTTe1-neurons. Our ﬁndings
of alterations in action potential characteristics, Na+ channel function
and synaptic responses in RTTe1-neurons resemble those in RTT-
miPSC-derived neurons (Farra et al., 2012) and extend the results
from other in vivo RTT mouse model systems (Chao et al., 2007; Dani
et al., 2005; Nelson et al., 2006; Zhang et al., 2010). Similarly, defects
in synapse formation and function have been previously reported in
human ES cell (Li et al., 2013) and hiPSC (Marchetto et al., 2010)models
of RTT with loss of both MECP2 isoforms. Reduced expression level of
sodium channels has been observed in several RTT models (Kim et al.,
2011; Zhang et al., 2010)whichmay contribute to the functional defects
we observed. Importantly, our ﬁnding that neuronal capacitance, a con-
sequence of smaller soma size (Golowasch et al., 2009; Limon et al.,
2005; Taneja et al., 2009), is reduced in RTTe1-neurons suggests that
manipulation of pathways that regulate cell size may correct some of
the functional defects. For instance, manipulation of the AKT/mTOR
pathway was shown to increase soma size and neurite complexity of
MECP2 null human ES cell-derived neurons (Li et al., 2013) although ef-
fects on electrophysiological phenotypes were not assessed. In conclu-
sion, our RTTe1 patient iPS cell model demonstrates that MECP2e1
isoform mutation affects the form and function of human neurons,
Fig. 7. RTTe1-neurons exhibit decreased mEPSC frequency and amplitude.
(A) Representative traces showingmEPSCs inWT- (upper) and RTTe1- (bottom) neurons,
and the inset showing averaged mEPSCs in the WT- (upper) and RTTe1- (bottom)
neurons, respectively. (B) Bar graph shows average mEPSC amplitude in WT-neurons
compared with RTTe1-neurons. (C) Histogram showing average mEPSC frequency in
WT-neurons compared with RTTe1-neurons. *P b 0.05, ***P b 0.001.
Fig. 6. RTTe1-neurons exhibit alterations in intrinsic membrane properties. (A) Histogram shows average input resistance in WT- and RTTe1-neurons. (B) Bar graph showing
average cell capacitance in WT-neurons compared with RTTe1-neurons. (C) Representative traces show evoked action potentials triggered by injecting a series of current
steps from−5 pA to+50 pA inWT- (Upper) and RTTe1- (Bottom) neurons. (D) A plot showing the numbers of action potentials evoked by injecting a series of current steps from+5pA
to +50 pA inWT- and RTTe1-neurons. (E) A plot depicting current–voltage relationships betweenWT- and RTTe1-neurons. Peak average inward currents (at−20mV) were compared
between WT- and RTTe1-neurons. *P b 0.05, **P b 0.01, ***P b 0.001.
44 U. Djuric et al. / Neurobiology of Disease 76 (2015) 37–45and shows that the cellular consequences of disease-causing alterna-
tively spliced transcripts can be deﬁned using patient iPS cells.
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